Department of Medicine, University of Western Australia, Perth, Western Australia, Australia.
Northwestern University, Chicago, Illinois, USA.
Curr Opin Infect Dis. 2021 Apr 1;34(2):175-179. doi: 10.1097/QCO.0000000000000710.
Coronavirus disease 2019 (COVID-19) has produced an extraordinary amount of literature in a short time period. This review focuses on what the new literature has provided in terms of more general information about the management of community-acquired pneumonia (CAP).
Measures taken to reduce the spread of COVID-19 have caused a significant drop in influenza worldwide. Improvements in imaging, especially ultrasound, and especially in the application of rapid molecular diagnosis are likely to have significant impact on the management of CAP. Therapeutic advances are so far limited.
COVID-19 has taught us that we can do far more to prevent seasonal influenza and its associated mortality, morbidity and economic cost. Improvements in imaging and pathogen diagnosis are welcome, as is the potential for secondary benefits of anti-COVID-19 therapies that may have reach effect on respiratory viruses other than severe acute respiratory syndrome coronavirus 2. As community-transmission is likely to persist for many years, recognition and treatment of severe acute respiratory syndrome coronavirus 2 will need to be incorporated into CAP guidelines moving forward.
新型冠状病毒病 2019（COVID-19）在短时间内产生了大量文献。本综述重点介绍了新文献在社区获得性肺炎（CAP）管理方面提供的更广泛的信息。
为减少 COVID-19 的传播而采取的措施导致全球范围内流感显著减少。影像学检查的改进，尤其是超声检查，尤其是快速分子诊断的应用，可能对 CAP 的管理产生重大影响。治疗进展目前有限。
COVID-19 让我们认识到，我们可以采取更多措施来预防季节性流感及其相关的死亡率、发病率和经济成本。影像学和病原体诊断的改进是受欢迎的，抗 COVID-19 治疗可能对除严重急性呼吸综合征冠状病毒 2 以外的呼吸道病毒产生继发益处，这也具有潜在意义。由于社区传播可能会持续多年，因此需要将严重急性呼吸综合征冠状病毒 2 的识别和治疗纳入 CAP 指南中。
